Companies › TaiRx
3 active drug programs in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CVM-1118 | – | Phase 2 | Neuroendocrine Tumors; Hepatocellular Carcinoma; HCC - Hepatocellular Carcinoma | Dec 2026 |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | HCC - Hepatocellular Carcinoma | Dec 2027 |
| TRX-920 Oral Gel Topoisomerase I inhibitor (SN38, active metabolite of irinotecan) | CAMPT | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03600233 | CVM-1118 | Phase 2 | Neuroendocrine Tumors | Oncology | Sep 2024 |
| NCT05257590 | CVM-1118 | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06143774 | TRX-920 Oral Gel | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07521852 | CVM-1118 | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Dec 2027 |
| NCT07521852 | Sintilimab | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Dec 2027 |
CStone Pharmaceuticals CSPC Megalith Biopharmaceutical CrystalGenomics Guangzhou Gloria Biosciences Tianjin ConjuStar Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.